Time-to-event endpoints show an increasing popularity in phase II cancer trials. The standard statistical tool for such one-armed survival trials is the one-sample log-rank test. Its distributional properties are commonly derived large sample limit. It however known from literature, that asymptotical approximations suffer when size small. There have already been several attempts to address this...
